Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Abreu Mendes, P (Author) FMUP; Francisco Cruz (Author) FMUP; Carlos Silva (Author) FMUP

Journal

Title: Current Opinion in Urology

Vol. 30

Pages: 486-490

ISSN: 0963-0643

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-00S-8DQ

DOI: 10.1097/mou.0000000000000774

Abstract (EN): Purpose of review This review aims to update the studies involving the treatment of lower urinary tract symptoms (LUTS) in neurogenic patients, published in the last two years. Recent findings Treatment of neurogenic LUTS (NLUTS) patients with beta 3 adrenoreceptor agonists was investigated in real-life conditions. A randomized controlled trial compared the efficacy of antimuscarinics versus onabotulinum toxin A in neurogenic patients. The use of desmopressin to treat nocturia in multiple sclerosis patients is also reported. The long-term treatment with BontA efficacy, its discontinuation, and possible strategies to maintain patients on treatment were also evaluated. Sacral neuromodulation and tibial nerve stimulation are continuously being evaluated in neurogenic patients, especially in the last years. Summary The management of urinary tract infections and vesical lithiasis, two common complications in NLUTS patients, and the management of both these patients was assessed in clinical trials. A trial evaluating the use of the anti-Nogo-A antibody after a spinal cord injury to facilitate neuronal rewiring and prevent or improve NLUTS was reported for the first time.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5